HISTAMINE PHOSPHATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HISTAMINE PHOSPHATE (HISTAMINE PHOSPHATE).
Histamine phosphate acts as a direct agonist at histamine H1 and H2 receptors, leading to vasodilation, increased capillary permeability, bronchoconstriction, and stimulation of gastric acid secretion.
| Metabolism | Primarily metabolized by histamine N-methyltransferase (HNMT) and diamine oxidase (DAO); also undergoes oxidative deamination by monoamine oxidase (MAO). |
| Excretion | Renal (primarily as metabolites); less than 2% excreted unchanged in urine. Biliary/fecal excretion negligible. |
| Half-life | Terminal elimination half-life is approximately 1–2 minutes; rapid due to enzymatic metabolism by histamine N-methyltransferase and diamine oxidase. Clinical context: ultra-short duration requires continuous IV infusion or repeated administration for sustained effect. |
| Protein binding | Approximately 15% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Approximately 0.5–0.7 L/kg (distribution largely limited to extracellular fluid; clinical meaning: rapid equilibration with tissues, does not cross blood-brain barrier significantly). |
| Bioavailability | Oral: <5% due to extensive first-pass metabolism. Subcutaneous: ~100% (complete but rapid metabolism). Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (seconds to 1 minute). Subcutaneous: 3–5 minutes. Intradermal: 1–3 minutes. Oral: not clinically used due to extensive first-pass metabolism. |
| Duration of Action | Intravenous: 5–15 minutes (transient hypotension and flushing). Subcutaneous: 30–60 minutes (wheal and flare response). Clinical notes: duration inversely related to dose; tachyphylaxis occurs with repeated dosing. |
0.01 mg subcutaneous once for diagnosis of achlorhydria; 0.02-0.04 mg/kg subcutaneous for challenge in pheochromocytoma (rarely used).
| Dosage form | INJECTABLE |
| Renal impairment | No standard adjustment defined; use with caution in severe renal impairment due to potential histamine accumulation. |
| Liver impairment | No specific Child-Pugh based adjustments; consider reduced metabolism leading to prolonged effects in severe hepatic impairment. |
| Pediatric use | Not established; safety and efficacy not determined. Avoid use in children. |
| Geriatric use | Start at lower end of dosing range; monitor for hypotension, flushing, and bradycardia due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HISTAMINE PHOSPHATE (HISTAMINE PHOSPHATE).
| Breastfeeding | No data on excretion in breast milk. M/P ratio unknown. Caution advised due to potential for adverse effects in infants; use only if clearly needed. |
| Teratogenic Risk | Teratogenic risk is determined by the severity of maternal anaphylaxis rather than direct drug effect. Histamine phosphate is not itself teratogenic; however, severe hypotension or hypoxia from anaphylaxis can cause fetal harm. Use only when clearly needed. Pregnancy category C. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to histamine or any component of the formulation","Severe hypotension","Unstable cardiovascular status","Asthma or history of bronchospasm","Active peptic ulcer disease"]
| Precautions | ["Risk of severe hypotension and shock due to vasodilation","May cause bronchospasm in patients with asthma or COPD","Use with caution in patients with cardiovascular disease","May exacerbate peptic ulcer disease due to increased gastric acid secretion"] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and oxygenation during administration. Fetal heart rate monitoring should be considered, especially in third trimester, as maternal hypotension may reduce placental perfusion. |
| Fertility Effects | No known adverse effects on fertility from histamine phosphate itself. Systemic anaphylaxis could theoretically impair reproductive function due to hemodynamic instability. |